Drug Trial Radar · NCT07609108
Pridopidine Phase 3 Study in Huntington's Disease
Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
400
Planned (sponsor's estimate)
Start
Jul 1, 2026
Primary completion
Jun 2028
Study completion Jun 2030
Sponsor
- Lead sponsor
- PrileniaIndustry
- Sponsor type
- Industry
- Collaborators
- Ferrer Internacional S.A.
- First posted
- May 27, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 23 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The goal of this clinical trial is to learn if pridopidine can slow the clinical decline of Huntington's Disease (HD) in adult participants. It will also inform about the safety of pridopidine. The main questions the study aims to answer are: Does pridopidine slow the overall worsening of HD over 1 year? Does pridopidine slow the worsening of specific aspects of HD over 1 year, namely the clinical progression, the ability to perform daily life activities (functional capacity), the mind's ability to process information (cognition), working of the muscles (motor function), and quality of life? Researchers will compare the drug pridopidine to a placebo (a look-alike substance that contains no drug) to see if pridopidine works better than placebo to treat HD. During the first year of the study, participants will have the same chance to receive either pridopidine or placebo. Participants will: Take 1 pridopidine or placebo capsule twice daily for 12 months. Visit the clinic 6 times within 1 year for checkups and tests. All participants who complete this 1-year placebo-controlled study period will roll over into an additional 2-year study period during which all participants will receive pridopidine treatment, including participants who had received placebo during the first year. During this additional 2-year treatment period participants will visit the clinic a total of 6 times for checkups and tests.
Conditions
- Huntington Disease
Interventions
PridopidineDrug
Pridopidine hard gelatin capsule
PlaceboDrug
Matched placebo hard gelatin capsule
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Composite Unified Huntington's Disease Rating Scale (cUHDRS)Time frame: Change from Baseline to Week 52
Locations
66 sites in 12 countries. Site status is shown where the registry gives one.
The University of Alabama at Birmingham
Birmingham, Alabama · Recruiting
University of California, San Diego
La Jolla, California · Recruiting
UCLA Medical Center
Los Angeles, California · Not yet recruiting
UC Davis Medical Center
Sacramento, California · Not yet recruiting
Georgetown University
Washington D.C., District of Columbia · Not yet recruiting
University of Miami-U Health Boca Raton
Boca Raton, Florida · Not yet recruiting
University of Florida (Norman Fixel Institute for Neurological Diseases)
Gainesville, Florida · Not yet recruiting
Northwestern University
Chicago, Illinois · Not yet recruiting
Rush University Medical Center
Chicago, Illinois · Not yet recruiting
University of Kansas Medical Center
Kansas City, Kansas · Not yet recruiting
Hereditary Neurological Disease Centre
Wichita, Kansas · Recruiting
Johns Hopkins University
Baltimore, Maryland · Not yet recruiting
Massachusetts General Hospital
Charlestown, Massachusetts · Not yet recruiting
Struthers Parkinson's Center / Health Partners Institute
Golden Valley, Minnesota · Recruiting
Columbia University
New York, New York · Recruiting
Duke University
Durham, North Carolina · Recruiting
University of Cincinnati
Cincinnati, Ohio · Not yet recruiting
Cleveland Clinic
Cleveland, Ohio · Recruiting
The Ohio State University
Columbus, Ohio · Recruiting
Oregon Health and Science University (OHSU)
Portland, Oregon · Not yet recruiting
Vanderbilt University Medical Center
Nashville, Tennessee · Recruiting
UT Health, Houston, McGovern Medical School
Houston, Texas · Recruiting
University of Vermont Medical Center
Burlington, Vermont · Not yet recruiting
EvergreenHealth Research Department
Kirkland, Washington · Not yet recruiting
University of Washington
Seattle, Washington · Recruiting
Hopital Erasme
Anderlecht, Belgium · Not yet recruiting
Cliniques Universitaires Saint-Luc
Woluwe-Saint-Lambert, Belgium · Not yet recruiting
University of Calgary
Calgary, Alberta, Canada · Not yet recruiting
University of Alberta
Edmonton, Alberta, Canada · Not yet recruiting
University of British Columbia
Vancouver, British Columbia, Canada · Not yet recruiting
North York General Hospital
Toronto, Ontario, Canada · Not yet recruiting
Centre Hospitalier de l'Universite de Montreal (CHUM)
Montreal, Quebec, Canada · Not yet recruiting
Vseobecna Fakultni Nemocnice V Praze
Prague, Czechia · Not yet recruiting
Centre Hospitalier Universitaire D'Angers
Angers, France · Not yet recruiting
CHU Henri Mondor (APHP)
Créteil, France · Not yet recruiting
Centre Hospitalier Universitaire Grenoble Alpes
La Tronche, France · Not yet recruiting
Centre Hospitalier Regional De Marseille
Marseille, France · Withdrawn
Universitaetsklinikum Aachen AöR
Aachen, Germany · Not yet recruiting
Katholisches Klinikum Bochum gGmbH
Bochum, Germany · Not yet recruiting
Universitätsklinikum Erlangen
Erlangen, Germany · Not yet recruiting
Showing 40 of 66 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.